APA (7th ed.) Citation

T, K., R, T., F, A., S, K., Y, M., R, O., . . . Y, I. (2024). Lysosomal degradation of PD-L1 is associated with immune-related adverse events during anti-PD-L1 immunotherapy in NSCLC patients. Frontiers in pharmacology, 15, 1384733. https://doi.org/10.3389/fphar.2024.1384733

Chicago Style (17th ed.) Citation

T, Kashiwada, et al. "Lysosomal Degradation of PD-L1 Is Associated with Immune-related Adverse Events During Anti-PD-L1 Immunotherapy in NSCLC Patients." Frontiers in Pharmacology 15 (2024): 1384733. https://doi.org/10.3389/fphar.2024.1384733.

MLA (9th ed.) Citation

T, Kashiwada, et al. "Lysosomal Degradation of PD-L1 Is Associated with Immune-related Adverse Events During Anti-PD-L1 Immunotherapy in NSCLC Patients." Frontiers in Pharmacology, vol. 15, 2024, p. 1384733, https://doi.org/10.3389/fphar.2024.1384733.